Skip to content

Main Navigation

Logo Vor BiopharmaNavigate to Vor Bio Medical Affairs homepage
  • Our Areas of Focus
    • Myasthenia Gravis (MG)
    • Sjögren’s
Disease (SjD)
  • Medical Congress Events
  • Publications
  • Sponsorships & Grants
  • Medical Information

Poster Presentation

Efficacy and safety of telitacicept in participants with Sjögren’s disease: Results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study

•

Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis: Results of a Phase 3 Study

•

A Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis: Trial Design Update

•

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (UPSTREAM MG)

•

Global Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis (RemeMG)

•

Telitacicept as a Novel BAFF/APRIL-Targeted Therapy for Sjögren’s Disease

•
Logo Vor Biopharma
  • Our Areas of Focus
    • Myasthenia Gravis (MG)
    • Sjögren’s
Disease (SjD)
  • Medical Congress Events
  • Publications
  • Sponsorships & Grants
  • Medical Information

© 2026 Vor Biopharma | Telitacicept is an investigational product that is not approved for use by the FDA, or any equivalent international regulator in respect of its use outside of China.

  • Privacy Policy
  • Terms of Use

By selecting “Yes,” you confirm that you are a U.S.-based healthcare professional and that you are accessing this site for scientific and medical information. This site is not intended for patients, caregivers, or non-U.S. audiences.